BioCentury | Apr 19, 2019
Clinical News
United BioPharma’s UB-421 suppresses HIV viremia in Phase II
...weeks after discontinuing ART. Data were published in The New England Journal of Medicine . United BioPharma Inc....
...Phase II/III trials of the mAb in combination with ART for HIV-1 infection. Hongjiang Li, Staff Writer UB-421 United BioPharma Inc....
...Phase II/III trials of the mAb in combination with ART for HIV-1 infection. Hongjiang Li, Staff Writer UB-421 United BioPharma Inc....
